.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers recently introduced a novel anti-TREM2 agonist antibody named 03O05. This therapeutic candidate shows significant potential for treating Alzheimer’s disease and multiple sclerosis. Unlike traditional antibodies that block receptor shedding, 03O05 preserves physiological processes. Therefore, it increases soluble TREM2 levels while activating neuroprotective microglial functions.
Triggering receptor expressed on myeloid cell-2 (TREM2) signaling is crucial for brain health. Specifically, it promotes the activity of disease-associated microglia. These cells clear toxic debris and maintain neuronal health. However, previous attempts to target this receptor often lowered soluble TREM2 levels. This reduction led to mixed clinical outcomes. Consequently, the team developed 03O05 as a ligand-mimetic solution.
In the 5xFAD mouse model of Alzheimer’s, the treatment yielded impressive results. Chronic administration of the antibody promoted the clearance of filamentous amyloid-beta plaques. Furthermore, it reduced microgliosis while enhancing phagocytosis. These actions effectively ameliorated neuronal dystrophy. Additionally, the researchers observed elevated soluble TREM2 levels in both the serum and brain tissue.
The study also examined the impact on multiple sclerosis using a cuprizone model. During the recovery phase, 03O05 significantly enhanced microglial phagocytosis. This process successfully reduced degraded myelin basic protein. As a result, the antibody promoted remyelination and improved structural integrity. Because this approach does not induce neuroinflammation, it offers a safer therapeutic profile. In summary, shedding-permissive agonism represents a promising strategy for neurodegenerative diseases.
Older agonist antibodies typically block the shedding of the TREM2 receptor. In contrast, 03O05 is shedding-permissive. This allows it to activate the receptor while increasing beneficial soluble TREM2 levels in the brain.
No, the study findings indicate that 03O05 promotes a neuroprotective microglial phenotype. It achieves therapeutic effects without inducing harmful neuroinflammation in mouse models.
The antibody helps clear amyloid-beta plaques and reduces damage to neurons. It also supports microglial health, which is essential for slowing the progression of Alzheimer’s disease.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Always consult a qualified medical professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Research identifies 03O05 as a shedding-permissive TREM2 agonist that clears amyloid plaques and promotes remyelination in Alzheimer's and MS mouse models....
5 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
